Xenetic Biosciences AI Stock Analysis
Want to see XBIO full AI Analyst Report?
Xenetic Biosciences (XBIO) AI Stock Analysis
Xenetic Biosciences
(NASDAQ:XBIO)
The overall score is deeply pressured by the company's poor financial health, with significant cash burn and declining revenue, and a bearish technical outlook. The primary positive offset is the transformative Santersus AG merger, which introduces a new strategic direction and clinical catalysts, though its execution risk and dilutive all-stock structure temper its immediate benefit.
Xenetic Biosciences (XBIO) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $3.28M
- Dividend Yield
- ―
- Average Volume (3M)
- 73.39K
- Price to Earnings (P/E)
- -0.9
- Beta (1Y)
- 0.82
- Revenue Growth
- 3.50%
- EPS Growth
- 22.76%
- Country
- US
- Employees
- 2
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Xenetic Biosciences Business Overview & Revenue Model
Company Description
Xenetic Biosciences, Inc. operates as a biopharmaceutical firm, primarily concentrating on the development of XCART. This cutting-edge personalized chimeric antigen receptor T cell (CAR T) platform is specifically engineered to identify and attack di...
Xenetic Biosciences Financial Statement Overview
Summary
Financial performance is critically weak. The company suffers from persistent, significant net losses and a 9.3% TTM revenue decline, despite a 100% gross margin. The only mitigating factor is a debt-free balance sheet, but this is overshadowed by rapidly eroding equity and deep negative returns.
Income Statement
18Very NegativeBalance Sheet
65PositiveCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.96M | 2.98M | 2.50M | 2.54M | 1.71M | 1.16M |
| Gross Profit | 2.96M | 2.98M | 2.50M | 2.54M | 1.71M | 1.16M |
| EBITDA | -3.66M | -2.68M | -3.81M | -4.13M | -6.53M | -5.61M |
| Net Income | -3.66M | -2.68M | -3.96M | -4.13M | -6.55M | -5.65M |
Balance Sheet | ||||||
| Total Assets | 6.32M | 8.36M | 6.90M | 10.61M | 14.72M | 19.82M |
| Cash, Cash Equivalents and Short-Term Investments | 5.81M | 7.88M | 6.17M | 8.98M | 13.10M | 18.24M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 27.04K |
| Total Liabilities | 1.90M | 968.02K | 894.26K | 809.59K | 1.07M | 1.42M |
| Stockholders Equity | 4.41M | 7.40M | 6.01M | 9.80M | 13.65M | 18.39M |
Cash Flow | ||||||
| Free Cash Flow | -2.32M | -2.29M | -2.82M | -4.11M | -5.15M | -4.74M |
| Operating Cash Flow | -2.32M | -2.29M | -2.82M | -4.11M | -4.65M | -4.74M |
| Investing Cash Flow | 0 | 0 | 0 | 0 | -500.00K | 0 |
| Financing Cash Flow | 4.00M | 4.00M | 0 | 0 | 0 | 11.45M |
Xenetic Biosciences Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XBIO, the sentiment is Negative. The current price of 1.40 is below the 20-day moving average (MA) of 1.81, below the 50-day MA of 2.14, and below the 200-day MA of 2.79, indicating a bearish trend. The MACD of -0.20 indicates Positive momentum. The RSI at 29.94 is Positive, neither overbought nor oversold. The STOCH value of 20.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XBIO.
Xenetic Biosciences Risk Analysis
Xenetic Biosciences disclosed 82 risk factors in its most recent earnings report. Xenetic Biosciences reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksXenetic Biosciences Peers Comparison
Overall Rating
APRE55Neutral
XBIO40Underperform
HCWB38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 55Neutral | $7.00M | -0.33 | -44.26% | ― | -99.32% | 67.31% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 40Underperform | $3.61M | -0.89 | -58.96% | ― | 3.50% | 22.76% | |
| 38Underperform | $2.31M | -0.03 | -63.04% | ― | 1502.05% | 77.12% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| XBIO | Xenetic Biosciences, Inc. | 1.40 | -1.06 | -43.09% | |
| ERNA | Eterna Therapeutics Inc. | 1.36 | -30.89 | -95.78% | |
| APRE | Aprea Therapeutics, Inc. | 0.23 | -0.94 | -80.43% | |
| HCWB | Hcw Biologics, Inc. | 0.75 | -12.27 | -94.25% |
Xenetic Biosciences Corporate Events
Xenetic Updates Investors on Santersus Share Exchange Plans
NeutralOn September 23, 2026, Xenetic Biosciences released an updated investor presentation tied to its pending share exchange transaction with Swiss-based Santersus AG, a deal first announced on September 16, 2026. The company also confirmed it will file a...
Xenetic Biosciences to Acquire Santersus AG in Merger
PositiveOn September 14, 2026, Xenetic Biosciences agreed to acquire all outstanding shares of Swiss medical device group Santersus AG via an all-stock share exchange that will make Santersus a wholly owned subsidiary, with its investors owning roughly 85 pe...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
